"The scrutiny that was attributed to other companies' results is not being attributed to Wyeth's quarter in our view, " says Robert Hazlett of SunTrust Robertson Humphrey.
"It's early days, but Merck is taking the long view, " says Robert Hazlett, an analyst at SunTrust Robinson Humphrey, who has a "buy" rating on Merck stock.
Robert Hazlett, an analyst at SunTrust Robinson Humphrey, said in a note to investors this morning that the news could mean that the drug, SU-11248, could be submitted to the U.S. Food and Drug Administration in the first quarter of this year, and that it could be approved by the end of 2005.